Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT04440332
Other study ID # 3001
Secondary ID
Status Not yet recruiting
Phase
First received
Last updated
Start date July 1, 2020
Est. completion date December 31, 2022

Study information

Verified date June 2020
Source Sichuan Cancer Hospital and Research Institute
Contact Xue-Feng Leng, M.D., Ph.D.
Phone +86 18702870755
Email leng724@163.com
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Neoadjuvant chemoradiotherapy treatment represents the standard approach for resectable locally advanced esophageal squamous cell carcinoma. The incidence of pulmonary infection and other perioperative complications were higher in patients who received esophagectomy and neoadjuvant chemoradiotherapy than those without neoadjuvant treatment and surgery patients. However, reliable clinical data can quantify the damage degree of immunologic function caused by chemotherapy and radiotherapy is still unknown. This project regards the level of lymphocyte and immunocyte in peripheral blood as a quantitative index to reflect the dynamic change of the immunologic function of patients with locally advanced esophageal squamous cell carcinoma after neoadjuvant chemoradiotherapy treatment. Meanwhile, the investigators will also investigate the relationship between the level of lymphocyte and immunocyte in peripheral blood and the response rate of neoadjuvant therapy.


Description:

Peripheral blood will be collected from patients who will undergo esophagectomy and/or neoadjuvant therapy. The setting time is before chemoradiotherapy, finishing chemoradiotherapy, pre-operation, postoperative day 1, day 3, day 5, and day 7. These blood samples will be used for detection and analysis in lymphocyte and immunocyte by flow cytometry.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 138
Est. completion date December 31, 2022
Est. primary completion date December 31, 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria:

- 1. Histologically confirmed locally advanced resectable thoracic ESCC; and requires esophagectomy alone or neoadjuvant chemoradiotherapy combined surgery treatment; Clinical stage T1-3N2-3M0 (AJCC 8 TNM classification);

- 2. At least one measurable lesion in accordance with RECIST 1.1;

- 3. Have a performance status of 0 or 1 on the ECOG Performance Scale;

- 4. Expected survival time is greater than 6 months;

- 5. Good organ function level: Hematology: white blood cell =3×10^9/L, neutrophil =1.5×10^9/L, hemoglobin =90 g/L and platelet =100×10^9/L; hepatic function: total bilirubin (TBIL) =1.5 times the upper limit of normal value (ULN), or total bilirubin > ULN, but direct bilirubin =ULN, ALT, AST =2.5 times the upper limit of normal value; Renal function: serum creatinine =1.5 times of ULN; Coagulation function: international normalized ratio (INR) or prothrombin time (PT) or activated partial thromboplastin time (aPTT) =1.5 x ULN;

- 6. The electrocardiograph was generally normal, and the left ventricular ejection fraction (LVEF) was =50%, Or the myocardial enzyme spectrum is in the normal range;

- 7. Normal thyroid function, defined as thyroid-stimulating hormone (TSH) in the normal range; If baseline TSH is beyond the normal range, subjects with total T3 (or FT3) and FT4 in the normal range will also be enrolled;

- 8. Female subjects of childbearing potential have a negative pregnancy test and must agree to take effective contraceptive measures during the study period and within 3 months after the last dose;

- 9. Be willing and able to provide written informed consent/assent for the trial.

Exclusion Criteria:

- 1. Patients with possible tracheoesophageal fistula or aortic esophageal fistula;

- 2. Patients with active autoimmune disease or documented autoimmune disease or symptoms requiring systemic hormone therapy or anti-autoimmune drug therapy;

- 3. Patients with immunodeficiency or who were still receiving systemic steroid hormone therapy (prednisone > 10 mg/ day or other equivalent drugs) or other forms of immunosuppressive therapy 7 days prior to the first dose of neoadjuvant therapy in this study;

- 4. Received anti-tumor therapy, including but not limited to chemotherapy, radiotherapy, immunotherapy, and targeted therapy, within 28 days prior to initial administration;

- 5. Patients with active infection who still required systemic treatment 7 days before the first dose of neoadjuvant therapy in this study;

- 6. Uncontrolled brain metastases;

- 7. Patients with interstitial lung disease, non-infectious pneumonia, or pulmonary fibrosis;

- 8. Patients with active tuberculosis (TB), who is receiving anti-TB treatment or who has received anti-TB treatment within 1 year before the first drug use

- 9. Patients with uncontrolled diabetes (fasting blood glucose =CTCAE level 2);

- 10. Peripheral neuropathy of degree II or above was found within 4 weeks before enrollment;

- 11.Patients who have received a foreign organ or stem cell transplant in the past;

- 12. Patients with allergies to the drugs or related ingredients in this study;

- 13. Patients with any serious or unstable medical condition or mental illness;

- 14. History of drug abuse or dependence;

- 15. Major organ disorders or diseases: liver and kidney dysfunction, history of myocardial infarction, unstable heart disease, chronic active hepatitis, etc;

- 16. History of other malignancies within 5 years (except for cured cervical cancer or basal cell carcinoma of the skin);

- 17. Patients who also participated in other clinical trials;

- 18. The researchers did not consider the patients suitable for any medical condition under study.

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
China Sichuan Cancer Hospital and Research Institute Chengdu Sichuan

Sponsors (1)

Lead Sponsor Collaborator
Sichuan Cancer Hospital and Research Institute

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Complete pathologic response rate and its relationship between peripheral blood of lymphocyte and immunocyte. Definition of complete pathologic response is "no cancer cell, including lympho nodes". 3 months
Primary Postoperative pulmonary infection rate and its relationship between peripheral blood of lymphocyte and immunocyte. The pulmonary infection after surgery included bacterial pneumonia and viral pneumonia and fungal pneumonia. 3 months
See also
  Status Clinical Trial Phase
Recruiting NCT05583916 - Same Day Discharge for Video-Assisted Thoracoscopic Surgery (VATS) Lung Surgery N/A
Completed NCT04448041 - CRANE Feasibility Study: Nutritional Intervention for Patients Undergoing Cancer Surgery in Low- and Middle-Income Countries
Completed NCT03213314 - HepaT1ca: Quantifying Liver Health in Surgical Candidates for Liver Malignancies N/A
Enrolling by invitation NCT05534490 - Surgery and Functionality in Older Adults N/A
Recruiting NCT04792983 - Cognition and the Immunology of Postoperative Outcomes
Terminated NCT04612491 - Pre-operative Consultation on Patient Anxiety and First-time Mohs Micrographic Surgery
Recruiting NCT06397287 - PROM Project Urology
Recruiting NCT04444544 - Quality of Life and High-Risk Abdominal Cancer Surgery
Completed NCT04204785 - Noise in the OR at Induction: Patient and Anesthesiologists Perceptions N/A
Completed NCT03432429 - Real Time Tissue Characterisation Using Mass Spectrometry REI-EXCISE iKnife Study
Completed NCT04176822 - Designing Animated Movie for Preoperative Period N/A
Recruiting NCT05370404 - Prescribing vs. Recommending Over-The-Counter (PROTECT) Analgesics for Patients With Postoperative Pain: N/A
Not yet recruiting NCT05467319 - Ferric Derisomaltose/Iron Isomaltoside and Outcomes in the Recovery of Gynecologic Oncology ERAS Phase 3
Recruiting NCT04602429 - Children's Acute Surgical Abdomen Programme
Completed NCT03124901 - Accuracy of Noninvasive Pulse Oximeter Measurement of Hemoglobin for Rainbow DCI Sensor N/A
Completed NCT04595695 - The Effect of Clear Masks in Improving Patient Relationships N/A
Recruiting NCT06103136 - Maestro 1.0 Post-Market Registry
Completed NCT05346588 - THRIVE Feasibility Trial Phase 3
Completed NCT04059328 - Novel Surgical Checklists for Gynecologic Laparoscopy in Haiti
Recruiting NCT03697278 - Monitoring Postoperative Patient-controlled Analgesia (PCA) N/A